UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life

Supportive care in cancer, 2012-12, Vol.20 (12), p.3141-3148

2012

Volltextzugriff (PDF)

The Cost of Psoriasis and Psoriatic Arthritis in 5 European Countries: A Systematic Review

Actas dermo-sifiliográficas (English ed.), 2016-09, Vol.107 (7), p.577-590

2016

Volltextzugriff (PDF)

Comparison of Expected Outcomes between Patients and Neurologists Using Kanoʼs Methodology in Symptomatic Migraine Treatment

The patient : patient-centered outcomes research, 2012-09, Vol.5 (3), p.147-162

2012

Volltextzugriff (PDF)

Evaluation of patients' and physicians' expectations and attributes of osteoarthritis treatment using Kano methodology

Quality of life research, 2012-10, Vol.21 (8), p.1391-1404

2012

Volltextzugriff (PDF)

Use of a structured migraine diary improves patient and physician communication about migraine disability and treatment outcomes

International journal of clinical practice (Esher), 2005-03, Vol.59 (3), p.281-286

2005

Volltextzugriff (PDF)

Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study

Actas dermo-sifiliográficas, 2013-11, Vol.104 (9), p.807-814

2013

Volltextzugriff (PDF)

Mental Health Self-Assessment in Patients With Moderate to Severe Psoriasis: An Observational, Multicenter Study of 1164 Patients in Spain (The VACAP Study)

Actas dermo-sifiliográficas, 2013-12, Vol.104 (10), p.897-903

2013

Volltextzugriff (PDF)

PSY39 - Azacitidine For The Treatment of Adult Patients (Age 65 or Older) with Acute Myeloid Leukemia And >30% Bone Marrow Blasts In Spain: Budget Impact Analysis

Value in health, 2016-11, Vol.19 (7), p.A581-A581

2016

Volltextzugriff (PDF)

PSS41 - Cost Per Responder of Apremilast Versus Infliximab Biosimilar, Etanercept, Adalimumab, Ustekinumab and Secukinumab in Patients with Moderate to Severe Psoriasis in Spain

Value in health, 2016-11, Vol.19 (7), p.A569-A569

2016

Volltextzugriff (PDF)

Cost Per Responder of Apremilast Versus Infliximab Biosimilar, Etanercept, Adalimumab, Ustekinumab and Secukinumab in Patients with Moderate to Severe Psoriasis in Spain

Value in health, 2016-11, Vol.19 (7), p.A569-A569

2016

Volltextzugriff (PDF)

Azacitidine For The Treatment of Adult Patients (Age 65 or Older) with Acute Myeloid Leukemia And >30% Bone Marrow Blasts In Spain: Budget Impact Analysis

Value in health, 2016-11, Vol.19 (7), p.A581-A581

2016

Volltextzugriff (PDF)

Factors affecting quality of life of asthma patients in Spain: The importance of patient education

Allergologia et immunopathologia, 2014-09, Vol.42 (5), p.476-484

2014

Volltextzugriff (PDF)

PATIENT‐REPORTED BENEFITS OF RIZATRIPTAN COMPARED WITH USUAL NON‐TRIPTAN THERAPY FOR MIGRAINE IN A PRIMARY CARE SETTING

International journal of clinical practice (Esher), 2003-11, Vol.57 (9), p.761-768

2003

Volltextzugriff (PDF)

Determinants of patient delay among tuberculosis cases in Spain

European journal of public health, 2004-06, Vol.14 (2), p.151-155

2004

Volltextzugriff (PDF)

Tuberculosis in Spain: epidemiological pattern and clinical practice

The international journal of tuberculosis and lung disease, 2002-04, Vol.6 (4), p.295

2002

Volltextzugriff (PDF)

PMS64 - Cost-Utility Analysis of Apremilast for The Treatment of Psoriatic Arthritis Patients In Spain

Value in health, 2015-11, Vol.18 (7), p.A645-A645

2015

Volltextzugriff (PDF)

PSS31 - Cost-Utility Analysis of Apremilast for The Treatment of Moderate to Severe Psoriasis In Spain

Value in health, 2015-11, Vol.18 (7), p.A420-A420

2015

Volltextzugriff (PDF)

PSS35 - Budget Impact Analysis of Apremilast on Moderate to Severe Psoriasis In Spain

Value in health, 2015-11, Vol.18 (7), p.A421-A421

2015

Volltextzugriff (PDF)

PMS69 - Budget Impact Analysis of Apremilast In Patients With Psoriatic Arthritis In Spain

Value in health, 2015-11, Vol.18 (7), p.A646-A646

2015

Volltextzugriff (PDF)

Comparison of Expected Outcomes between Patients and Neurologists Using Kano’s Methodology in Symptomatic Migraine Treatment

The patient : patient-centered outcomes research, 2012, Vol.5 (3), p.147-162

2012

Volltextzugriff (PDF)

Cost-Utility Analysis of Apremilast for The Treatment of Psoriatic Arthritis Patients In Spain

Value in health, 2015-11, Vol.18 (7), p.A645-A645

2015

Volltextzugriff (PDF)

Budget Impact Analysis of Apremilast on Moderate to Severe Psoriasis In Spain

Value in health, 2015-11, Vol.18 (7), p.A421-A421

2015

Volltextzugriff (PDF)

Budget Impact Analysis of Apremilast In Patients With Psoriatic Arthritis In Spain

Value in health, 2015-11, Vol.18 (7), p.A646-A646

2015

Volltextzugriff (PDF)

Cost-Utility Analysis of Apremilast for The Treatment of Moderate to Severe Psoriasis In Spain

Value in health, 2015-11, Vol.18 (7), p.A420-A420

2015

Volltextzugriff (PDF)

PND47 APPLICATION OF THE KANO METHODOLOGY FOR EVALUATING MIGRAINE TREATMENT EXPECTATIONS AMONG PATIENTS TREATED BY NEUROLOGISTS IN SPAIN:THE MIGREXX STUDY

Value in health, 2010, Vol.13 (7), p.A397-A397

2010

Volltextzugriff (PDF)

1 – 25 von 85

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(72)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life

The Cost of Psoriasis and Psoriatic Arthritis in 5 European Countries: A Systematic Review

Comparison of Expected Outcomes between Patients and Neurologists Using Kanoʼs Methodology in Symptomatic Migraine Treatment

Evaluation of patients' and physicians' expectations and attributes of osteoarthritis treatment using Kano methodology

Use of a structured migraine diary improves patient and physician communication about migraine disability and treatment outcomes

Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study

Mental Health Self-Assessment in Patients With Moderate to Severe Psoriasis: An Observational, Multicenter Study of 1164 Patients in Spain (The VACAP Study)

PSY39 - Azacitidine For The Treatment of Adult Patients (Age 65 or Older) with Acute Myeloid Leukemia And >30% Bone Marrow Blasts In Spain: Budget Impact Analysis

PSS41 - Cost Per Responder of Apremilast Versus Infliximab Biosimilar, Etanercept, Adalimumab, Ustekinumab and Secukinumab in Patients with Moderate to Severe Psoriasis in Spain

Cost Per Responder of Apremilast Versus Infliximab Biosimilar, Etanercept, Adalimumab, Ustekinumab and Secukinumab in Patients with Moderate to Severe Psoriasis in Spain

Azacitidine For The Treatment of Adult Patients (Age 65 or Older) with Acute Myeloid Leukemia And >30% Bone Marrow Blasts In Spain: Budget Impact Analysis

Factors affecting quality of life of asthma patients in Spain: The importance of patient education

PATIENT‐REPORTED BENEFITS OF RIZATRIPTAN COMPARED WITH USUAL NON‐TRIPTAN THERAPY FOR MIGRAINE IN A PRIMARY CARE SETTING

Determinants of patient delay among tuberculosis cases in Spain

Tuberculosis in Spain: epidemiological pattern and clinical practice

PMS64 - Cost-Utility Analysis of Apremilast for The Treatment of Psoriatic Arthritis Patients In Spain

PSS31 - Cost-Utility Analysis of Apremilast for The Treatment of Moderate to Severe Psoriasis In Spain

PSS35 - Budget Impact Analysis of Apremilast on Moderate to Severe Psoriasis In Spain

PMS69 - Budget Impact Analysis of Apremilast In Patients With Psoriatic Arthritis In Spain

Comparison of Expected Outcomes between Patients and Neurologists Using Kano’s Methodology in Symptomatic Migraine Treatment

Cost-Utility Analysis of Apremilast for The Treatment of Psoriatic Arthritis Patients In Spain

Budget Impact Analysis of Apremilast on Moderate to Severe Psoriasis In Spain

Budget Impact Analysis of Apremilast In Patients With Psoriatic Arthritis In Spain

Cost-Utility Analysis of Apremilast for The Treatment of Moderate to Severe Psoriasis In Spain

PND47 APPLICATION OF THE KANO METHODOLOGY FOR EVALUATING MIGRAINE TREATMENT EXPECTATIONS AMONG PATIENTS TREATED BY NEUROLOGISTS IN SPAIN:THE MIGREXX STUDY

Suchergebnisse filtern